H.R. 6832 · 117th Congress

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Stage
In committee
Sponsor
Michael Cloud
Introduced
2022-02-25
Latest action
2022-02-28 · Referred to the Subcommittee on Health.

Action history

  1. 2022-02-28Referred to the Subcommittee on Health.
  2. 2022-02-25Introduced in House
  3. 2022-02-25Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  4. 2022-02-25Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.